Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881301 | 0.94 | CA14 (0.40) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL19437619 | 0.91 | CA14 (0.45) | CA14SSTR4MEN1KMT2AHDAC6 | |
| SCHEMBL31618313 | 0.91 | CA14 (0.45) | CA14SSTR4MEN1KMT2AHDAC6 | |
| SCHEMBL31584056 | 0.91 | CA14 (0.45) | CA14SSTR4MEN1KMT2AHDAC6 | |
| SCHEMBL23296185 | 0.89 | CA14 (0.46) | CA14SSTR4MEN1KMT2AHDAC6 | |
| SCHEMBL15444409 | 0.86 | MEN1 (0.44) | MEN1KMT2AHDAC6HDAC1HDAC2 | |
| SCHEMBL14706366 | 0.86 | MEN1 (0.44) | MEN1KMT2AHDAC6HDAC1HDAC2 | |
| SCHEMBL22771162 | 0.86 | MEN1 (0.44) | MEN1KMT2AHDAC6HDAC1HDAC2 | |
| SCHEMBL722740 | 0.86 | MEN1 (0.44) | MEN1KMT2AHDAC6HDAC1HDAC2 | |
| SCHEMBL225095 | 0.86 | MEN1 (0.44) | MEN1KMT2AHDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226492-A1 | Immunoconjugates Targeting HER2 | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220226491-A1 | Immunoconjugates Targeting PD-L1 | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020190762-A1 | MACROMOLECULE-SUPPORTED TLR AGONISTS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226492-A1 | Immunoconjugates Targeting HER2 | ERBB2, EGFR, ERBB3 | CA14 610/4885SSTR4 418/4885MEN1 3651/4885 |
| US-20220226491-A1 | Immunoconjugates Targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CA14 1557/4885SSTR4 3383/4885MEN1 3164/4885 |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | CD47, FCGR3B, FCGR1A | CA14 14/4885SSTR4 472/4885MEN1 2083/4885 |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | CA14 3893/4885SSTR4 1112/4885MEN1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.